Author:
Schwabe Christian,Wynne Chris,Dyapa Dayaker Reddy,Prajapati Arpitkumar,Dadke Disha
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Xia X, Gong C, Zhang Y, Xiong H. The history and development of HER2 inhibitors. Pharmaceuticals (Basel). 2023;16(10):1450. https://doi.org/10.3390/ph16101450.
2. Ishikawa T, Ichikawa Y, Shimizu D, Sasaki T, Tanabe M, Chishima T, et al. The role of HER-2 in breast cancer. J Surg Sci. 2014;2(1):4–9.
3. Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19(1):40–50.
4. Pimentel FF, Morgan G, Tiezzi DG, de Andrade JM. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceut Med. 2018;32(5):319–25. https://doi.org/10.1007/s40290-018-0247-5.
5. Greenblatt K, Khaddour K. Trastuzumab. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.